Name
Granulocyte-Macrophage Colony Stimulating Factor
Alternate Names
GM CSF
Filgrastim (Neupogen)
Sargramostim (Lukine)
Abbreviations
None
Category
Ancillary Agent
Subcategory
None
NSC Number
None
Primary Site
None
Histology
None
Remarks
GM-CSF products main indication is for treatment or prevention of neutropenia related infections induced by cancer myelosuppressive treatment and thus classified as ancillary agents in SEER*Rx
Although GM-CSF products do not have FDA indication for treatment of cancer, they are used in the clinical practice in combination with ethiodized oil (such as Lipiodol or Ethiodol) and embolizing agent (such as gelatin sponge, polyvinyl sponge, polyvinyl alcohol particles, resorbable microspheres) for immunoembolization of liver metastasis in uveal melanoma. Code GM-CSF as "Other" therapy only if given for immunoembolization of liver metastasis.
Although GM-CSF products do not have FDA indication for treatment of cancer, they are used in the clinical practice in combination with ethiodized oil (such as Lipiodol or Ethiodol) and embolizing agent (such as gelatin sponge, polyvinyl sponge, polyvinyl alcohol particles, resorbable microspheres) for immunoembolization of liver metastasis in uveal melanoma. Code GM-CSF as "Other" therapy only if given for immunoembolization of liver metastasis.
Coding
Please see remarks for additional information
Home